Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of High-dose CKD-385 in Healthy Volunteers (Fed Conditions)
NCT04651881Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Oct 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-385 in cardiovascular disease (CVD) (6 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve to the last measurable concentration at 48 hours and Maximum Plasma Concentration at 48 hours. Status: unknown.
02
Drugs
CKD-385
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT04651881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04651881.